Zhao Fangrui, Yang Dashuai, Xu Tangpeng, He Jiahui, Guo Jin, Li Xiangpan
Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Front Oncol. 2023 Jul 3;13:1210064. doi: 10.3389/fonc.2023.1210064. eCollection 2023.
Pancreatic acinar cell carcinoma (PACC) is a rare pancreatic malignancy with unique clinical, molecular, and morphologic features. The long-term survival of patients with PACC is substantially better than that of patients with ductal adenocarcinoma of the pancreas. Surgical resection is considered the first choice for treatment; however, there is no standard treatment option for patients with inoperable disease. The patient with metastatic PACC reported herein survived for more than 5 years with various treatments including chemotherapy, radiotherapy, antiangiogenic therapy and combined immunotherapy.
胰腺腺泡细胞癌(PACC)是一种罕见的胰腺恶性肿瘤,具有独特的临床、分子和形态学特征。PACC患者的长期生存率明显高于胰腺导管腺癌患者。手术切除被认为是首选治疗方法;然而,对于无法手术的患者,尚无标准的治疗方案。本文报道的转移性PACC患者通过化疗、放疗、抗血管生成治疗和联合免疫治疗等多种治疗方法存活了5年以上。